June has seen a slew of executive hires, promotions, exits and layoffs across the healthcare sector. For example, CVS Health ...

Hinge Health and Omada Health. During a recent panel discussion, venture capitalists shared lessons learned about health tech ...

After a major drop during the height of the pandemic (2020–2022), the share of nurses ages 55+ in the workforce rebounded in 2024 — from a low of 31% in 2022 back up to 40%. More than 100,000 ...

AstraZeneca is paying CSPC Pharmaceutical Group $110 million up front to tap that China-based biotech’s artificial intelligence-driven technology for discovering and developing novel oral drugs ...

The acquisition comes six months after Arcadia sold its value-based care service division to Guidehealth. Through the two deals, Arcadia is sharpening its focus on providing the right data and ...

The Supreme Court upheld the constitutionality of an Affordable Care Act provision requiring insurance coverage of certain preventive services without cost-sharing. Many healthcare leaders applauded ...

Many primary care physicians are not participating in value-based payment models. A new study details why and potential solutions. By Marissa Plescia on August 18, 2024 10:53 am ...

In an interview, Redox CEO Trip Hofer shared why the company is well-positioned to facilitate the push for the nationwide exchange of electronic health information facilitated by the TEFCA framework.

Despite their necessity, beds and surfaces do not always receive proportional attention and innovation — even as the risks associated with prolonged bed rest remain a key priority for caregivers.

Given their relationship with payers, providers, and consumers, PBMs are uniquely capable of leveraging AI to take friction out of pharmacy benefits. But integrating AI and machine learning is not ...

Empowering frontline leaders: Enabling meaningful engagement One of the most impactful actions health systems can take is empowering frontline leaders. Reducing administrative burdens through ...

But despite the significance of the FDA’s withdrawal more than eight years ago, prescribing behavior has lagged, ultimately putting patients at risk. Even with a slight decline in fenofibrate ...